臨床前 CRO 市場 - 2018-2028 年全球產業規模、佔有率、趨勢、機會和預測，按服務、模型類型（患者衍生類器官模型、患者衍生異種移植模型）、最終用途行業、地區、競爭細分

2022 年，全球臨床前 CRO 市場估值達到 58.9 億美元，預計在預測期內強勁成長，預計年複合成長率 (CAGR) 為 8.53%，到 2028 年預計將達到 96.2 億美元。

介紹：

臨床前 CRO（合約研究組織）是專門提供用於各種工業應用的水性著色劑的實體，包括食品加工、印刷油墨、木材著色劑、紡織品加工等。這些著色劑對液體和基材具有卓越的選擇性吸收性，使其優於顏料等其他賦色材料。臨床前 CRO 具有卓越的吸收特性，可在應用於基材時改變其物理和結構特性。然而，值得注意的是，臨床前 CRO 的耐光性有限，保存期限也相對較短。因此，它們主要用於在成品製造中需要高透明度的表面塗層、食品和印刷應用。臨床前CRO可以根據其在特定介質或底物中的溶解度進行分類，包括鹼性臨床前CRO、脂溶性臨床前CRO和金屬絡合物臨床前CRO。

市場概況
預測期	2024-2028
2022 年市場規模	58.9億美元
2028 年市場規模	96.2億美元
2023-2028 年年複合成長率	8.53%
成長最快的細分市場	患者衍生類器官 (PDO) 模型
最大的市場	北美洲

主要市場促進因素：

1. 日益成長的外包趨勢推動市場成長：

外包的成長趨勢是全球臨床前合約研究組織（CRO）市場擴張的重要動力。製藥和生物技術公司擴大選擇將其臨床前研究和開發活動委託給專門的 CRO，而不是在內部進行。這項策略轉變使這些公司能夠節省與維護內部設施、設備和人員相關的成本。 CRO 通常擁有成熟的基礎設施和專業知識，這有助於高效且經濟高效地執行臨床前研究。外包臨床前研究使企業能夠將內部資源分配到臨床試驗、監管事務和商業化等核心活動上，從而提高整體營運效率。臨床前 CRO 配備了各個科學學科的專家，提供專業知識和經驗。公司可以利用這些專業知識，而無需建立和維護廣泛的內部團隊。此外，CRO 投資用於臨床前研究的最先進技術和設備，為公司提供先進的工具，而無需大量資本投資。外包還為公司提供了根據專案需求擴展臨床前活動的靈活性，這對於應對藥物開發的動態性質至關重要。臨床前 CRO 通常已經建立了流程和工作流程，從而加快了研究執行速度並縮短了開發時間，從而加快了藥物開發過程。

2. 臨床前階段藥物數量不斷增加：

處於臨床前階段的藥物數量不斷增加，大大促進了全球臨床前合約研究組織（CRO）市場的成長。隨著製藥和生物技術公司不斷開發更多潛在候選藥物，對 CRO 提供的臨床前研究和測試服務的需求不斷成長。隨著越來越多的候選藥物進入臨床前階段，更需要進行各種臨床前研究，例如安全性評估、功效測試和藥物動力學研究。 CRO 有能力同時處理多個項目，並擁有滿足不同候選藥物（從小分子到生物製劑和新型療法）多樣化需求的專業知識。本公司可能不具備同時進行多項臨床前研究所需的內部資源、設備或設施。因此，外包給CRO可以最佳化資源配置。候選藥物數量的不斷增加凸顯了簡化和加速臨床前開發流程的重要性。 CRO 憑藉其既定的工作流程和專業知識，有助於加快研究速度，從而更快地進入臨床階段。管理大量臨床前專案對公司來說可能具有挑戰性。 CRO 提供專門的風險管理策略和工具來應對臨床前研究的複雜性，減少代價高昂的失敗的可能性。

3.研發成本上升推動市場成長：

製藥和生物技術產業研發（R＆D）成本不斷上升是全球臨床前合約研究組織（CRO）市場的重要驅動力。隨著研發費用持續上升，企業擴大轉向臨床前CRO來最佳化其藥物開發流程、提高成本效益並提高整體效率。內部臨床前研究設施，包括基礎設施、設備、人員和營運費用，可能會對公司的預算造成壓力。外包給臨床前 CRO 提供了更具成本效益的替代方案，使公司能夠控制和管理其研發支出。透過將臨床前研究外包給 CRO，公司可以利用 CRO 現有的基礎設施、設備和經驗豐富的人員，最大限度地減少對大量資本投資和持續營運成本的需求。將臨床前工作外包給 CRO 有助於減輕與失敗的候選藥物相關的財務風險。 CRO 進行嚴格的臨床前測試，在開發過程的早期發現潛在問題，並減少代價高昂的臨床試驗失敗的可能性。 CRO 通常會聘請各個科學和監管領域的專家，無需龐大的內部團隊即可獲得廣泛的專業知識。這種專業知識可以最佳化研究設計、執行和資料解釋。監管要求和遵守品質標準的需要可能會增加研發成本。臨床前 CRO 在應對這些監管環境方面擁有豐富的經驗，可確保研究按照指南進行。 CRO 進行的高效臨床前研究加速了藥物開發過程，使公司能夠更快地將有前景的候選藥物投入臨床試驗。這種上市速度可以顯著節省成本並增加收入。臨床前CRO提供安全性評估、藥效測試、藥物動力學、毒理學研究等多種服務，企業可依自身需求選擇特定服務，最佳化資源配置。

主要市場挑戰：

1. 法規遵從與品質保證：

監管合規性和品質保證給全球合約研究組織 (CRO) 市場帶來了重大挑戰，特別是在臨床前研究方面。製藥和生物技術產業受到美國食品藥物管理局 (FDA) 和歐洲藥品管理局 (EMA) 等衛生當局的嚴格監管。確保嚴格按照這些規定進行臨床前研究對於獲得監管部門批准並進入臨床試驗至關重要。不同地區和國家的監管要求可能有所不同，因此臨床前 CRO 必須與來自不同地理位置的客戶合作，引導和協調不同的監管框架，這可能既複雜又耗時。不遵守監管指南可能會導致延誤、成本增加，甚至候選藥物在後期開發階段被拒絕。因此，CRO 必須全面了解不斷變化的法規，以最大限度地降低不合規風險。

2. 數據解釋與報告：

數據解釋和報告給全球合約研究組織 (CRO) 市場帶來了重大挑戰，特別是在臨床前研究方面。準確且有意義的資料解釋和報告對於藥物開發中的明智決策至關重要。臨床前研究會產生複雜的多維資料，需要深入了解科學原理、統計分析和生物學背景才能得出準確的結論。生物系統本質上是可變的，CRO 必須考慮資料解釋中的這種可變性，以區分真實影響和背景噪音並識別有意義的趨勢。現代科技在臨床前研究中產生大量資料，管理和分析這些「大資料」可能令人難以承受，需要複雜的生物資訊工具和專業知識。不正確的資料解釋可能會

3. 溝通與協作：

溝通和協作挑戰可能會影響全球合約研究組織 (CRO) 市場，特別是在臨床前研究背景下。 CRO 與其客戶之間的有效溝通與協作對於專案成功至關重要。溝通不良可能會導致 CRO 和客戶之間的期望不一致，這可能導致交付成果不符合期望。在日益全球化的行業中，CRO和客戶可能來自不同的國家和文化，語言障礙和文化差異會阻礙有效的溝通和協作。臨床前研究通常涉及複雜的實驗設計和方法，將這些複雜性傳達給客戶並確保他們對技術方面的理解可能具有挑戰性。溝通延遲可能會導致專案中斷、錯過最後期限並增加成本。清晰、及時的溝通對於保持專案正常進行至關重要，CRO 必須優先考慮清晰、透明和主動的溝通實踐。

主要市場趨勢：

1. 虛擬審判數量的增加：

全球合約研究組織 (CRO) 市場的一個重要趨勢是虛擬試驗數量的增加，這正在改變臨床研究的進行方式。虛擬試驗也稱為分散臨床試驗，利用科技遠端收集參與者的資料，減少實地考察的需要。這些試驗使患者能夠在家中參與，從而提高患者招募率和保留率。 CRO 正在調整策略，透過遠距醫療、穿戴式裝置和行動應用程式虛擬地吸引患者，通常與技術供應商合作，整合用於遠端資料收集、患者監測、電子知情同意和遠距醫療諮詢的數位工具。這種轉變需要選擇、實施和管理這些技術的專業知識，以及強大的資料管理解決方案來處理大量遠端患者產生的資料。虛擬試驗減少了對實體試驗站點的依賴，簡化了操作，提高了效率，並降低了與站點基礎設施相關的成本。此外，虛擬試驗擴大了對更多樣化的患者群體的訪問範圍，包括以前因地理限制而被排除在外的患者群體，這擴大了潛在的參與者範圍並增強了試驗結果的普遍性。

細分洞見：

服務洞察：

2022 年，臨床前 CRO 市場以毒理學測試為主，預計未來幾年將繼續擴大。毒理學測試是全球合約研究組織 (CRO) 市場中至關重要且占主導地位的部分，尤其是在藥物開發的臨床前階段。它評估新化合物對生物體的潛在不利影響，有助於在進入臨床試驗之前確定其安全性。確保潛在候選藥物的安全是製藥和生物技術公司的首要任務。毒理學研究提供了與新化合物相關的潛在風險和危害的關鍵資料，預計該細分市場從 2023 年到 2030 年將經歷最高的年複合成長率(CAGR)。

模型類型洞察：

2022 年，臨床前 CRO 市場由 PDO（患者衍生類器官）領域主導，預計未來幾年將繼續擴大。 PDO 模型是源自於患者組織的3D細胞培養物，與傳統細胞系相比，非常模仿器官的複雜結構和功能。這種高度的患者相關性使得 PDO 成為研究疾病機制、藥物反應和個人化治療的寶貴工具。朝向個人化醫療邁進需要能夠複製患者對治療的特異性反應的模型，而 PDO 模型使研究人員能夠研究個別患者的細胞如何對不同的治療做出反應，從而促進制定量身定做的治療策略。

最終用途產業見解：

2022年，臨床前CRO市場由生物製藥公司主導，預計這種主導地位在未來幾年將繼續擴大。生物製藥公司通常優先考慮其核心競爭力，例如研究、創新和商業化。將某些職能（包括臨床前和臨床研究）外包給 CRO 可以使這些公司將內部資源集中在關鍵領域。 CRO 為生物製藥公司提供了一種經濟高效的解決方案，消除了對基礎設施、設備、人員以及與內部研究活動相關的營運成本的大量投資。 CRO 在進行藥物開發的各個方面提供專業知識和經驗，包括臨床前測試、臨床試驗、資料分析、監管提交等。生物製藥公司可以從獲得這些專業技能中受益，而無需維持龐大的內部團隊。

區域見解：

亞太地區已成為全球臨床前 CRO 市場的領導者。該地區是專注於早期藥物發現的成熟 CRO 的所在地，例如 Charles River Laboratories 或 LabCorp。美國在臨床前試驗外包市場中也發揮著重要作用，因為許多生物製藥公司更願意將臨床前試驗外包給美國的 CRO，以利用 FDA 批准的研究性新藥申請流程。

目錄

第 1 章：產品概述

• 市場定義
• 市場範圍
  • 涵蓋的市場
  • 研究年份
  • 主要市場區隔

第 2 章：研究方法

• 研究目的
• 基線方法
• 主要產業夥伴
• 主要協會和二手資料來源
• 預測方法
• 數據三角測量與驗證
• 假設和限制

第 3 章：執行摘要

• 市場概況
• 主要市場細分概述
• 主要市場參與者概述
• 重點地區/國家概況
• 市場促進因素、挑戰、趨勢概述

第 4 章：客戶之聲

第 5 章：全球臨床前 CRO 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按服務分類（生物分析和 DMPK 研究、毒理學測試、化合物管理、化學、安全藥理學、其他）
  • 按模型類型（患者衍生類器官 (PDO) 模型、患者衍生異種移植模型）
  • 依最終用途產業（生物製藥公司、政府和學術機構、醫療器材公司）
  • 按公司分類 (2022)
  • 按地區
• 市場地圖

第 6 章：北美臨床前 CRO 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按服務
  • 按型號類型
  • 按最終用途行業
  • 按國家/地區
• 北美：國家分析
  • 美國
  • 墨西哥
  • 加拿大

第 7 章：歐洲臨床前 CRO 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按服務
  • 按型號類型
  • 按最終用途行業
  • 按國家/地區
• 歐洲：國家分析
  • 法國
  • 德國
  • 英國
  • 義大利
  • 西班牙

第 8 章：亞太地區臨床前 CRO 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按服務
  • 按型號類型
  • 按最終用途行業
  • 按國家/地區
• 亞太地區：國家分析
  • 中國
  • 印度
  • 韓國
  • 日本
  • 澳洲

第 9 章：南美洲臨床前 CRO 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按服務
  • 按型號類型
  • 按最終用途行業
  • 按國家/地區
• 南美洲：國家分析
  • 巴西
  • 阿根廷
  • 哥倫比亞

第 10 章：中東和非洲臨床前 CRO 市場展望

• 市場規模及預測
  • 按價值
• 市佔率及預測
  • 按服務
  • 按型號類型
  • 按最終用途行業
  • 按國家/地區
• MEA：國家分析
  • 南非臨床前CRO
  • 沙烏地阿拉伯臨床前CRO
  • 阿拉伯聯合大公國臨床前CRO

第 11 章：市場動態

• 促進要素
• 挑戰

第 12 章：市場趨勢與發展

• 最近的發展
• 產品發布
• 併購

第 13 章：大環境分析

第 14 章：波特的五力分析

• 產業競爭
• 新進入者的潛力
• 供應商的力量
• 客戶的力量
• 替代產品的威脅

第15章：競爭格局

• 商業概覽
• 公司概況
• 產品與服務
• 財務（上市公司）
• 最近的發展
• SWOT分析
  • Eurofins Scientific SE
  • PRA Health Sciences, Inc.
  • Wuxi AppTec
  • Medpace, Inc.
  • Charles River Laboratories International, Inc.
  • PPD (Thermo Fisher Scientific, Inc.)
  • SGA SA
  • Intertek Group Plc (IGP)
  • LABCORP Inc
  • Crown Bioscience Inc

第 16 章：策略建議

The Global Preclinical CRO Market reached a valuation of USD 5.89 Billion in 2022 and is poised for robust growth in the forecast period, with a projected Compound Annual Growth Rate (CAGR) of 8.53% and expected to reach USD 9.62 Billion through 2028.

Introduction:

Preclinical CROs (Contract Research Organizations) are specialized entities that provide aqueous-based colorants used in various industrial applications, including food processing, printing inks, wood stain, textile processing, and more. These colorants offer superior selective absorptivity for liquids and substrates, making them preferable to other color-imparting materials like pigments. Preclinical CROs possess exceptional absorption characteristics that allow for the modification of their physical and structural properties when applied to substrates. However, it's important to note that Preclinical CROs have limited resistance to light and a relatively shorter shelf life. As a result, they are primarily used in surface coating, food, and printing applications that require high levels of transparency in the manufacturing of finished products. Preclinical CROs can be categorized based on their solubility in a specific medium or substrate, including basic Preclinical CROs, fat-soluble Preclinical CROs, and metal complex Preclinical CROs.

Market Overview
Forecast Period	2024-2028
Market Size 2022	USD 5.89 Billion
Market Size 2028	USD 9.62 Billion
CAGR 2023-2028	8.53%
Fastest Growing Segment	Patient Derived Organoid (PDO) Model
Largest Market	North America

Key Market Drivers:

1. Increasing Outsourcing Trends Drive Market Growth:

The growing trend of outsourcing is a significant driver behind the expansion of the Global Preclinical Contract Research Organization (CRO) market. Pharmaceutical and biotechnology companies are increasingly opting to delegate their preclinical research and development activities to specialized CROs rather than conducting them in-house. This strategic shift allows these companies to realize cost savings related to maintaining in-house facilities, equipment, and personnel. CROs often possess established infrastructure and expertise, which leads to the efficient and cost-effective execution of preclinical studies. Outsourcing preclinical research allows companies to allocate their internal resources to core activities such as clinical trials, regulatory affairs, and commercialization, thereby enhancing overall operational efficiency. Preclinical CROs are staffed with experts in various scientific disciplines, providing specialized knowledge and experience. This expertise can be leveraged by companies without the need to build and maintain extensive in-house teams. Moreover, CROs invest in state-of-the-art technologies and equipment for preclinical research, providing companies with access to advanced tools without substantial capital investments. Outsourcing also offers companies the flexibility to scale their preclinical activities based on project needs, which is crucial for navigating the dynamic nature of drug development. Preclinical CROs often have established processes and workflows, resulting in faster study execution and reduced development timelines, accelerating the drug development process.

2. Rising Number Of Drugs In Preclinical Phases:

The increasing number of drugs in preclinical phases contributes significantly to the growth of the Global Preclinical Contract Research Organization (CRO) market. As pharmaceutical and biotechnology companies continue to develop a larger pipeline of potential drug candidates, the demand for preclinical research and testing services provided by CROs grows. With more drug candidates entering preclinical phases, there is a greater need for conducting various preclinical studies, such as safety assessments, efficacy testing, and pharmacokinetics studies. CROs are equipped to handle multiple projects simultaneously and possess expertise in accommodating the diverse needs of different drug candidates, ranging from small molecules to biologics and novel therapies. Companies may not have the internal resources, equipment, or facilities required to conduct multiple preclinical studies concurrently. Therefore, outsourcing to CROs optimizes resource allocation. The increasing number of drug candidates underscores the importance of streamlined and accelerated preclinical development processes. CROs, with their established workflows and expertise, help expedite studies, enabling quicker progression to clinical phases. Managing a large number of preclinical programs can be challenging for companies. CROs provide specialized risk management strategies and tools to navigate the complexities of preclinical research, reducing the potential for costly failures.

3. Rising R&D Costs Drive Market Growth:

The escalating costs of research and development (R&D) in the pharmaceutical and biotechnology industries are a significant driver of the Global Preclinical Contract Research Organization (CRO) market. As R&D expenses continue to rise, companies increasingly turn to preclinical CROs to optimize their drug development processes, enhance cost-effectiveness, and improve overall efficiency. In-house preclinical research facilities, including infrastructure, equipment, staffing, and operational expenses, can strain a company's budget. Outsourcing to preclinical CROs offers a more cost-effective alternative, enabling companies to contain and manage their R&D expenditures. By outsourcing preclinical studies to CROs, companies can leverage the CROs' established infrastructure, equipment, and experienced personnel, minimizing the need for substantial capital investments and ongoing operational costs. Outsourcing preclinical work to CROs helps mitigate the financial risks associated with failed drug candidates. CROs conduct rigorous preclinical testing, identifying potential issues early in the development process and reducing the likelihood of costly clinical trial failures. CROs often employ specialists in various scientific and regulatory fields, providing access to a broad range of expertise without the need for extensive in-house teams. This expertise optimizes study design, execution, and data interpretation. Regulatory requirements and the need for adherence to quality standards can contribute to R&D costs. Preclinical CROs are experienced in navigating these regulatory landscapes, ensuring studies are conducted in compliance with guidelines. Efficient preclinical research conducted by CROs accelerates the drug development process, enabling companies to move promising candidates into clinical trials more quickly. This speed-to-market can result in significant cost savings and revenue generation. Preclinical CROs offer a variety of services, such as safety assessments, efficacy testing, pharmacokinetics, toxicology studies, and more, allowing companies to choose specific services based on their needs and optimizing resource allocation.

Key Market Challenges:

1. Regulatory Compliance and Quality Assurance:

Regulatory compliance and quality assurance present significant challenges to the Global Contract Research Organization (CRO) market, particularly in the context of preclinical research. The pharmaceutical and biotechnology industries are heavily regulated by health authorities such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Ensuring that preclinical studies are conducted in strict accordance with these regulations is essential for obtaining regulatory approvals and advancing to clinical trials. Regulatory requirements can vary between regions and countries, making it necessary for Preclinical CROs working with clients from different geographic locations to navigate and harmonize diverse regulatory frameworks, which can be complex and time-consuming. Failure to comply with regulatory guidelines can lead to delays, increased costs, or even the rejection of drug candidates in later development stages. Therefore, CROs must maintain a thorough understanding of evolving regulations to minimize the risk of non-compliance.

2. Data Interpretation and Reporting:

Data interpretation and reporting present significant challenges to the Global Contract Research Organization (CRO) market, particularly in the context of preclinical research. Accurate and meaningful data interpretation and reporting are essential for informed decision-making in drug development. Preclinical studies generate complex and multidimensional data that require a deep understanding of scientific principles, statistical analyses, and biological context to draw accurate conclusions. Biological systems are inherently variable, and CROs must account for this variability in data interpretation to differentiate true effects from background noise and identify meaningful trends. Modern technologies generate vast amounts of data in preclinical studies, and managing and analyzing this "big data" can be overwhelming, requiring sophisticated bioinformatics tools and expertise. Incorrect data interpretation can

lead to false positives (detecting effects that are not real) or false negatives (missing real effects), both of which can have serious consequences for drug development decisions.

3. Communication and Collaboration:

Communication and collaboration challenges can impact the Global Contract Research Organization (CRO) market, particularly in the context of preclinical research. Effective communication and collaboration between CROs and their clients are essential for successful project outcomes. Poor communication can lead to misaligned expectations between CROs and clients, potentially resulting in deliverables that do not meet expectations. In an increasingly globalized industry, CROs and clients may come from different countries and cultures, and language barriers and cultural differences can hinder effective communication and collaboration. Preclinical studies often involve complex experimental designs and methodologies, and communicating these intricacies to clients and ensuring their understanding of the technical aspects can be challenging. Delays in communication can lead to project disruptions, missed deadlines, and increased costs. Clear and timely communication is crucial to keep projects on track, and CROs must prioritize clear, transparent, and proactive communication practices.

Key Market Trends:

1. Increase in the Number of Virtual Trials:

A significant trend in the Global Contract Research Organization (CRO) market is the increase in the number of virtual trials, which is transforming how clinical research is conducted. Virtual trials, also known as decentralized clinical trials, utilize technology to remotely collect data from participants, reducing the need for physical site visits. These trials enable patients to participate from their homes, resulting in higher patient recruitment and retention rates. CROs are adapting their strategies to engage patients virtually through telehealth, wearables, and mobile apps, often partnering with technology providers to integrate digital tools for remote data collection, patient monitoring, electronic informed consent, and telemedicine consultations. This shift requires expertise in selecting, implementing, and managing these technologies, as well as robust data management solutions to handle large volumes of remote patient-generated data. Virtual trials reduce reliance on physical trial sites, streamlining operations, enhancing efficiency, and reducing costs associated with site infrastructure. Additionally, virtual trials expand access to a more diverse patient population, including those previously excluded due to geographic constraints, which broadens the potential pool of participants and enhances the generalizability of trial results.

Segmental Insights:

Service Insights:

In 2022, the Preclinical CRO market was dominated by Toxicology testing and is predicted to continue expanding over the coming years. Toxicology testing is a crucial and dominant segment within the Global Contract Research Organization (CRO) market, especially in the preclinical stage of drug development. It assesses the potential adverse effects of new compounds on living organisms, helping to determine their safety profiles before progressing to clinical trials. Ensuring the safety of potential drug candidates is a top priority for pharmaceutical and biotechnology companies. Toxicology studies provide critical data on the potential risks and hazards associated with new compounds, and this segment is projected to experience the highest compound annual growth rate (CAGR) from 2023 to 2030.

Model Type Insight:

In 2022, the Preclinical CRO market was dominated by the PDO (Patient-Derived Organoid) segment and is predicted to continue expanding over the coming years. PDO models are three-dimensional cell cultures derived from patient tissues, closely mimicking the complex architecture and functionality of organs compared to traditional cell lines. This high level of patient relevance makes PDOs valuable tools for studying disease mechanisms, drug responses, and personalized treatments. The move toward personalized medicine requires models that replicate patient-specific responses to treatments, and PDO models enable researchers to study how individual patients' cells respond to different therapies, facilitating the development of tailored treatment strategies.

End-Use Industry Insights:

In 2022, the Preclinical CRO market was dominated by biopharmaceutical companies, and this dominance is predicted to continue expanding over the coming years. Biopharmaceutical companies often prioritize their core competencies, such as research, innovation, and commercialization. Outsourcing certain functions, including preclinical and clinical research, to CROs allows these companies to concentrate their internal resources on critical areas. CROs offer a cost-effective solution for biopharmaceutical companies, eliminating the need for heavy investments in infrastructure, equipment, personnel, and operational costs associated with in-house research activities. CROs provide specialized expertise and experience in conducting various aspects of drug development, including preclinical testing, clinical trials, data analysis, regulatory submissions, and more. Biopharmaceutical companies benefit from accessing these specialized skills without maintaining an extensive in-house team.

Regional Insights:

The Asia Pacific region has established itself as the leader in the Global Preclinical CRO Market. The region is home to established CROs focused on early drug discovery, such as Charles River Laboratories or LabCorp. The United States also plays a significant role in the preclinical trial outsourcing market, as many biopharma companies prefer to outsource their preclinical trials to U.S.-based CROs to take advantage of the FDA-approved Investigational New Drug application process.

Key Market Players

• Eurofins Scientific SE
• PRA Health Sciences, Inc.
• Wuxi AppTec, Medpace, Inc.
• Charles River Laboratories International, Inc.
• PPD (Thermo Fisher Scientific, Inc.)
• SGA SA
• Intertek Group Plc (IGP)
• LABCORP Inc
• Crown Bioscience Inc

Report Scope:

In this report, the Global Preclinical CRO Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Preclinical CRO Market, By Service:

• Bioanalysis and DMPK studies
• Toxicology Testing
• Compound Management
• Chemistry
• Safety Pharmacology
• Others

Preclinical CRO Market, By Model:

• Patient Derived Organoid (PDO) Model
• Patient derived xenograft model

Preclinical CRO Market, By End-User:

• Biopharmaceutical Companies
• Government and Academic Institutes
• Medical Device Companies

Global Preclinical CRO Market, By region:

• North America
• United States
• Canada
• Mexico
• Asia-Pacific
• China
• India
• South Korea
• Australia
• Japan
• Europe
• Germany
• France
• United Kingdom
• Spain
• Italy
• South America
• Brazil
• Argentina
• Colombia
• Middle East & Africa
• South Africa
• Saudi Arabia
• UAE

Competitive Landscape

• Company Profiles: Detailed analysis of the major companies present in the Global Preclinical CRO Market.

Available Customizations:

• Global Preclinical CRO Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Preclinical CRO Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Service (Bioanalysis and DMPK Studies, Toxicology Testing, Compound Management, Chemistry, Safety Pharmacology, Others)
  • 5.2.2. By Model Type (Patient Derived Organoid (PDO) Model, Patient derived xenograft model)
  • 5.2.3. By End-Use Industry (Biopharmaceutical Companies, Government and Academic Institutes, Medical Device Companies)
  • 5.2.4. By Company (2022)
  • 5.2.5. By Region
• 5.3. Market Map

6. North America Preclinical CRO Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Service
  • 6.2.2. By Model Type
  • 6.2.3. By End-Use Industry
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Preclinical CRO Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Service
      • 6.3.1.2.2. By Model Type
      • 6.3.1.2.3. By End-Use Industry
  • 6.3.2. Mexico Preclinical CRO Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Service
      • 6.3.2.2.2. By Model Type
      • 6.3.2.2.3. By End-Use Industry
  • 6.3.3. Canada Preclinical CRO Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Service
      • 6.3.3.2.2. By Model Type
      • 6.3.3.2.3. By End-Use Industry

7. Europe Preclinical CRO Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Service
  • 7.2.2. By Model Type
  • 7.2.3. By End-Use Industry
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. France Preclinical CRO Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Service
      • 7.3.1.2.2. By Model Type
      • 7.3.1.2.3. By End-Use Industry
  • 7.3.2. Germany Preclinical CRO Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Service
      • 7.3.2.2.2. By Model Type
      • 7.3.2.2.3. By End-Use Industry
  • 7.3.3. United Kingdom Preclinical CRO Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Service
      • 7.3.3.2.2. By Model Type
      • 7.3.3.2.3. By End-Use Industry
  • 7.3.4. Italy Preclinical CRO Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Service
      • 7.3.4.2.2. By Model Type
      • 7.3.4.2.3. By End-Use Industry
  • 7.3.5. Spain Preclinical CRO Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Service
      • 7.3.5.2.2. By Model Type
      • 7.3.5.2.3. By End-Use Industry

8. Asia-Pacific Preclinical CRO Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Service
  • 8.2.2. By Model Type
  • 8.2.3. By End-Use Industry
  • 8.2.4. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China Preclinical CRO Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Service
      • 8.3.1.2.2. By Model Type
      • 8.3.1.2.3. By End-Use Industry
  • 8.3.2. India Preclinical CRO Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Service
      • 8.3.2.2.2. By Model Type
      • 8.3.2.2.3. By End-Use Industry
  • 8.3.3. South Korea Preclinical CRO Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Service
      • 8.3.3.2.2. By Model Type
      • 8.3.3.2.3. By End-Use Industry
  • 8.3.4. Japan Preclinical CRO Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Service
      • 8.3.4.2.2. By Model Type
      • 8.3.4.2.3. By End-Use Industry
  • 8.3.5. Australia Preclinical CRO Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Service
      • 8.3.5.2.2. By Model Type
      • 8.3.5.2.3. By End-Use Industry

9. South America Preclinical CRO Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Service
  • 9.2.2. By Model Type
  • 9.2.3. By End-Use Industry
  • 9.2.4. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil Preclinical CRO Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Service
      • 9.3.1.2.2. By Model Type
      • 9.3.1.2.3. By End-Use Industry
  • 9.3.2. Argentina Preclinical CRO Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Service
      • 9.3.2.2.2. By Model Type
      • 9.3.2.2.3. By End-Use Industry
  • 9.3.3. Colombia Preclinical CRO Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Service
      • 9.3.3.2.2. By Model Type
      • 9.3.3.2.3. By End-Use Industry

10. Middle East and Africa Preclinical CRO Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Service
  • 10.2.2. By Model Type
  • 10.2.3. By End-Use Industry
  • 10.2.4. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa Preclinical CRO Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Service
      • 10.3.1.2.2. By Model Type
      • 10.3.1.2.3. By End-Use Industry
  • 10.3.2. Saudi Arabia Preclinical CRO Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Service
      • 10.3.2.2.2. By Model Type
      • 10.3.2.2.3. By End-Use Industry
  • 10.3.3. UAE Preclinical CRO Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Service
      • 10.3.3.2.2. By Model Type
      • 10.3.3.2.3. By End-Use Industry

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. PESTLE Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Product

15. Competitive Landscape

• 15.1. Business Overview
• 15.2. Company Snapshot
• 15.3. Products & Services
• 15.4. Financials (In case of listed companies)
• 15.5. Recent Developments
• 15.6. SWOT Analysis
  • 15.6.1. Eurofins Scientific SE
  • 15.6.2. PRA Health Sciences, Inc.
  • 15.6.3. Wuxi AppTec
  • 15.6.4. Medpace, Inc.
  • 15.6.5. Charles River Laboratories International, Inc.
  • 15.6.6. PPD (Thermo Fisher Scientific, Inc.)
  • 15.6.7. SGA SA
  • 15.6.8. Intertek Group Plc (IGP)
  • 15.6.9. LABCORP Inc
  • 15.6.10. Crown Bioscience Inc

16. Strategic Recommendations